Oncological Emergencies:@0.672868:0.035749:0.914547:0.035749:0.914547:0.019993:0.672868:0.019993:0.016722:0.011738:0.012450:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005330:0.010314:0.018049:0.012508:0.005805:0.012950:0.012508:0.011738:0.012450:0.003848:0.012508:0.007466
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
115:@0.950254:0.038184:0.981863:0.038184:0.981863:0.018587:0.950254:0.018587:0.010536:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Figure 2. Legend:@0.085667:0.096562:0.227926:0.096562:0.227926:0.080172:0.085667:0.080172:0.009756:0.005272:0.011257:0.011218:0.007158:0.010160:0.003887:0.010680:0.005003:0.003887:0.009660:0.010160:0.011257:0.010160:0.011276:0.011468
CVAD: central venous access device; Na: sodium; K: potassium; Cl: chloride; TCO2: total carbon dioxide; SIRS: :@0.084848:0.128213:0.903961:0.128213:0.903961:0.114207:0.084848:0.114207:0.012515:0.008930:0.011392:0.011453:0.004264:0.004264:0.009960:0.010006:0.009390:0.005219:0.004634:0.010514:0.003079:0.004264:0.008528:0.010006:0.009390:0.010083:0.009360:0.005973:0.004264:0.010514:0.009960:0.009960:0.010006:0.005973:0.005973:0.004264:0.010545:0.010006:0.008528:0.003079:0.009960:0.010006:0.004264:0.004264:0.011392:0.010514:0.004264:0.004264:0.005973:0.010083:0.010545:0.003079:0.009360:0.014439:0.004264:0.004264:0.009098:0.004264:0.004264:0.010499:0.010083:0.005219:0.010514:0.005973:0.005973:0.003079:0.009360:0.014439:0.004264:0.004264:0.012515:0.003079:0.004264:0.004264:0.009960:0.009390:0.003079:0.010083:0.004634:0.003079:0.010545:0.010006:0.004264:0.004264:0.006558:0.012515:0.013377:0.008528:0.004264:0.004264:0.005219:0.010083:0.005219:0.010514:0.003079:0.004264:0.009960:0.010514:0.004634:0.010499:0.010083:0.009390:0.004264:0.010545:0.003079:0.010083:0.007389:0.003079:0.010545:0.010006:0.004264:0.004264:0.007666:0.003479:0.009344:0.007666:0.004264:0.004264
systemic inflammatory response syndrome; LRT: lower respiratory tract; URT: upper respiratory tract; GI: gastro-:@0.084848:0.142912:0.896147:0.142912:0.896147:0.128906:0.084848:0.128906:0.005973:0.008251:0.005973:0.005219:0.010006:0.014439:0.003079:0.009960:0.004264:0.003079:0.009390:0.003733:0.003733:0.010514:0.014439:0.014439:0.010514:0.005219:0.010083:0.004634:0.008251:0.004264:0.004570:0.010006:0.005973:0.010499:0.010083:0.009390:0.005973:0.010006:0.004264:0.005973:0.008251:0.009390:0.010545:0.004570:0.010083:0.014439:0.010006:0.004264:0.004264:0.007112:0.009433:0.006599:0.004264:0.004264:0.003079:0.010083:0.012792:0.010006:0.004634:0.004264:0.004570:0.010006:0.005973:0.010499:0.003079:0.004634:0.010514:0.005219:0.010083:0.004634:0.008251:0.004264:0.005219:0.004634:0.010514:0.009960:0.005219:0.004264:0.004264:0.010083:0.009433:0.006599:0.004264:0.004264:0.009360:0.010499:0.010499:0.010006:0.004634:0.004264:0.004570:0.010006:0.005973:0.010499:0.003079:0.004634:0.010514:0.005219:0.010083:0.004634:0.008251:0.004264:0.005219:0.004634:0.010514:0.009960:0.005219:0.004264:0.004264:0.013424:0.003479:0.004264:0.004264:0.010360:0.010514:0.005973:0.005219:0.004570:0.010083:0.005111
intestinal tract; GU: genito-urinary tract; O2: oxygen; IV: intravenous; MASCC: Multinational Association for :@0.084848:0.157611:0.873558:0.157611:0.873558:0.143606:0.084848:0.143606:0.003079:0.009390:0.005219:0.010006:0.005973:0.005219:0.003079:0.009390:0.010514:0.003079:0.004264:0.005219:0.004634:0.010514:0.009960:0.005219:0.004264:0.004264:0.013424:0.010083:0.004264:0.004264:0.010360:0.010006:0.009390:0.003079:0.005219:0.010083:0.005111:0.009360:0.004634:0.003079:0.009390:0.010514:0.004634:0.008251:0.004264:0.005219:0.004634:0.010514:0.009960:0.005219:0.004264:0.004264:0.013377:0.008528:0.004264:0.004264:0.010083:0.007389:0.008251:0.010360:0.010006:0.009390:0.004264:0.004264:0.003479:0.010793:0.004264:0.004264:0.003079:0.009390:0.005219:0.004634:0.010514:0.008528:0.010006:0.009390:0.010083:0.009360:0.005973:0.004264:0.004264:0.014147:0.011392:0.007666:0.012515:0.012515:0.004264:0.004264:0.014147:0.009360:0.003079:0.005219:0.003079:0.009390:0.010514:0.005219:0.003079:0.010083:0.009390:0.010514:0.003079:0.004264:0.011392:0.005973:0.005973:0.010083:0.009960:0.003079:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264:0.004834:0.010083:0.004634:0.004264
Supportive Care in Cancer; PO: per os (by mouth).:@0.084848:0.172310:0.460703:0.172310:0.460703:0.158305:0.084848:0.158305:0.007666:0.009360:0.010499:0.010499:0.010083:0.004634:0.005219:0.003079:0.008528:0.010006:0.004264:0.012515:0.010514:0.004569:0.010006:0.004264:0.003079:0.009390:0.004264:0.012515:0.010514:0.009390:0.009960:0.010006:0.004634:0.004264:0.004264:0.009113:0.013377:0.004264:0.004264:0.010499:0.010006:0.004634:0.004264:0.010083:0.005973:0.004264:0.005680:0.010499:0.008251:0.004264:0.014439:0.010083:0.009360:0.005219:0.009390:0.005680:0.004264
* The Northern Ireland Cancer Network states that neutropaenic sepsis is a “time-dependent” condition, the :@0.084848:0.191172:0.891559:0.191172:0.891559:0.177166:0.084848:0.177166:0.006542:0.004264:0.006558:0.009390:0.010006:0.004264:0.011392:0.010083:0.004634:0.005219:0.009390:0.010006:0.004954:0.009390:0.004264:0.003479:0.004569:0.010006:0.003079:0.010514:0.009390:0.010545:0.004264:0.012515:0.010514:0.009390:0.009960:0.010006:0.004634:0.004264:0.011392:0.010006:0.005219:0.012792:0.010083:0.004634:0.007728:0.004264:0.005973:0.005219:0.010514:0.005219:0.010006:0.005973:0.004264:0.005219:0.009390:0.010514:0.005219:0.004264:0.009390:0.010006:0.009360:0.005219:0.004570:0.010083:0.010499:0.010514:0.010006:0.009390:0.003079:0.009960:0.004264:0.005973:0.010006:0.010499:0.005973:0.003079:0.005973:0.004264:0.003079:0.005973:0.004264:0.010514:0.004264:0.007728:0.005219:0.003079:0.014439:0.010006:0.005111:0.010545:0.010006:0.010499:0.010006:0.009390:0.010545:0.010006:0.009390:0.005219:0.007451:0.004264:0.009960:0.010083:0.009390:0.010545:0.003079:0.005219:0.003079:0.010083:0.009390:0.004264:0.004264:0.005219:0.009390:0.010006:0.004264
successful management of which is dependent upon the early recognition of the likelihood that the cancer :@0.084848:0.205871:0.890765:0.205871:0.890765:0.191866:0.084848:0.191866:0.005973:0.009360:0.009960:0.009960:0.010006:0.005973:0.005973:0.004834:0.009360:0.003079:0.004264:0.014439:0.010514:0.009390:0.010514:0.010360:0.010006:0.014439:0.010006:0.009390:0.005219:0.004264:0.010083:0.004834:0.004264:0.012792:0.009390:0.003079:0.009960:0.009390:0.004264:0.003079:0.005973:0.004264:0.010545:0.010006:0.010499:0.010006:0.009390:0.010545:0.010006:0.009390:0.005219:0.004264:0.009360:0.010499:0.010083:0.009390:0.004264:0.005219:0.009390:0.010006:0.004264:0.010006:0.010514:0.004634:0.003079:0.008251:0.004264:0.004570:0.010006:0.009960:0.010083:0.010360:0.009390:0.003079:0.005219:0.003079:0.010083:0.009390:0.004264:0.010083:0.004834:0.004264:0.005219:0.009390:0.010006:0.004264:0.003079:0.003079:0.007728:0.010006:0.003079:0.003079:0.009390:0.010083:0.010083:0.010545:0.004264:0.005219:0.009390:0.010514:0.005219:0.004264:0.005219:0.009390:0.010006:0.004264:0.009960:0.010514:0.009390:0.009960:0.010006:0.004634:0.004264
patient’s problem represents a neutropaenic fever/sepsis syndrome . Since more than 70 percent of cancer :@0.084848:0.220570:0.890299:0.220574:0.890299:0.206569:0.084848:0.206565:0.010499:0.010514:0.005219:0.003079:0.010006:0.009390:0.005219:0.005403:0.005973:0.004264:0.010499:0.004569:0.010083:0.010499:0.003079:0.010006:0.014439:0.004264:0.004569:0.010006:0.010499:0.004569:0.010006:0.005973:0.010006:0.009390:0.005219:0.005973:0.004264:0.010514:0.004264:0.009390:0.010006:0.009360:0.005219:0.004570:0.010083:0.010499:0.010514:0.010006:0.009390:0.003079:0.009960:0.004264:0.004834:0.010006:0.008528:0.010006:0.004634:0.006727:0.005973:0.010006:0.010499:0.005973:0.003079:0.005973:0.004264:0.005973:0.008251:0.009390:0.010545:0.004569:0.010083:0.014439:0.010006:0.004968:0.004264:0.004264:0.007666:0.003079:0.009390:0.009960:0.010006:0.004264:0.014439:0.010083:0.004570:0.010006:0.004264:0.005219:0.009390:0.010514:0.009390:0.004264:0.008528:0.008528:0.004264:0.010499:0.010006:0.004524:0.009960:0.010006:0.009390:0.005219:0.004264:0.010083:0.004834:0.004264:0.009960:0.010514:0.009390:0.009960:0.010006:0.004634:0.268046
1:@0.587194:0.215579:0.592166:0.215579:0.592166:0.207414:0.587194:0.207414:0.004972
treatment-related syndromes, including neutropaenic fever, manifest within four to six weeks of systemic :@0.084846:0.235273:0.859748:0.235273:0.859748:0.221268:0.084846:0.221268:0.005219:0.004569:0.010006:0.010514:0.005219:0.014439:0.010006:0.009390:0.005219:0.005111:0.004570:0.010006:0.003079:0.010514:0.005219:0.010006:0.010545:0.004264:0.005973:0.008251:0.009390:0.010545:0.004570:0.010083:0.014439:0.010006:0.005973:0.004264:0.004264:0.003079:0.009390:0.009960:0.003079:0.009360:0.010545:0.003079:0.009390:0.010360:0.004264:0.009390:0.010006:0.009360:0.005219:0.004569:0.010083:0.010499:0.010514:0.010006:0.009390:0.003079:0.009960:0.004264:0.004834:0.010006:0.008528:0.010006:0.003014:0.004264:0.004264:0.014439:0.010514:0.009390:0.003079:0.004834:0.010006:0.005973:0.005219:0.004264:0.012792:0.003079:0.005219:0.009390:0.003079:0.009390:0.004264:0.004834:0.010083:0.009360:0.004634:0.004264:0.005219:0.010083:0.004264:0.005973:0.003079:0.007389:0.004264:0.012792:0.010006:0.010006:0.007728:0.005973:0.004264:0.010083:0.004834:0.004264:0.005973:0.008251:0.005973:0.005219:0.010006:0.014439:0.003079:0.009960:0.004264
treatment , the Northern Ireland Cancer Network has recommended a history of chemotherapy within the past :@0.084846:0.249972:0.916843:0.249972:0.916843:0.235967:0.084846:0.235967:0.005219:0.004569:0.010006:0.010514:0.005219:0.014439:0.010006:0.009390:0.005219:0.004968:0.004264:0.004264:0.005219:0.009390:0.010006:0.004264:0.011392:0.010083:0.004634:0.005219:0.009390:0.010006:0.004954:0.009390:0.004264:0.003479:0.004570:0.010006:0.003079:0.010514:0.009390:0.010545:0.004264:0.012515:0.010514:0.009390:0.009960:0.010006:0.004634:0.004264:0.011392:0.010006:0.005219:0.012792:0.010083:0.004634:0.007728:0.004264:0.009390:0.010514:0.005973:0.004264:0.004570:0.010006:0.009960:0.010083:0.014439:0.014439:0.010006:0.009390:0.010545:0.010006:0.010545:0.004264:0.010514:0.004264:0.009390:0.003079:0.005973:0.005219:0.010083:0.004634:0.008251:0.004264:0.010083:0.004834:0.004264:0.009960:0.009390:0.010006:0.014439:0.010083:0.005219:0.009390:0.010006:0.004634:0.010514:0.010499:0.008251:0.004264:0.012792:0.003079:0.005219:0.009390:0.003079:0.009390:0.004264:0.005219:0.009390:0.010006:0.004264:0.010499:0.010514:0.005973:0.005219:0.004264
2:@0.159420:0.244977:0.164392:0.244977:0.164392:0.236812:0.159420:0.236812:0.004972
six weeks as a sensitive discriminator to detect patients with neutropaenic fever/sepsis syndromes by triage :@0.084853:0.264671:0.881378:0.264671:0.881378:0.250666:0.084853:0.250666:0.005973:0.003079:0.007389:0.004264:0.012792:0.010006:0.010006:0.007728:0.005973:0.004264:0.010514:0.005973:0.004264:0.010514:0.004264:0.005973:0.010006:0.009390:0.005973:0.003079:0.005219:0.003079:0.008528:0.010006:0.004264:0.010545:0.003079:0.005973:0.009960:0.004634:0.003079:0.014439:0.003079:0.009390:0.010514:0.005219:0.010083:0.004634:0.004264:0.005219:0.010083:0.004264:0.010545:0.010006:0.005219:0.010006:0.009960:0.005219:0.004264:0.010499:0.010514:0.005219:0.003079:0.010006:0.009390:0.005219:0.005973:0.004264:0.012792:0.003079:0.005219:0.009390:0.004264:0.009390:0.010006:0.009360:0.005219:0.004570:0.010083:0.010499:0.010514:0.010006:0.009390:0.003079:0.009960:0.004264:0.004834:0.010006:0.008528:0.010006:0.004634:0.006727:0.005973:0.010006:0.010499:0.005973:0.003079:0.005973:0.004264:0.005973:0.008251:0.009390:0.010545:0.004570:0.010083:0.014439:0.010006:0.005973:0.004264:0.010499:0.008251:0.004264:0.005219:0.004634:0.003079:0.010514:0.010360:0.010006:0.004264
services in health-care facilities .:@0.084853:0.279370:0.324092:0.279370:0.324092:0.265365:0.084853:0.265365:0.005973:0.010006:0.004634:0.008528:0.003079:0.009960:0.010006:0.005973:0.004264:0.003079:0.009390:0.004264:0.009390:0.010006:0.010514:0.003079:0.005219:0.009390:0.005111:0.009960:0.010514:0.004569:0.010006:0.004264:0.004834:0.010514:0.009960:0.003079:0.003079:0.003079:0.005219:0.003079:0.010006:0.005973:0.004977:0.004264
1:@0.314854:0.274376:0.319827:0.274376:0.319827:0.266211:0.314854:0.266211:0.004972
¶:@0.084855:0.299878:0.092506:0.299878:0.092506:0.284015:0.084855:0.284015:0.007651
 SIRS is a clinical syndrome that is a form of dysregulated inflammation. The term SIRS has routinely been :@0.092352:0.298232:0.847664:0.298232:0.847664:0.284227:0.092352:0.284227:0.004110:0.007512:0.003325:0.009190:0.007512:0.004110:0.002925:0.005819:0.004110:0.010360:0.004110:0.009806:0.002925:0.002925:0.009236:0.002925:0.009806:0.010360:0.002925:0.004110:0.005819:0.008097:0.009236:0.010391:0.004417:0.009929:0.014286:0.009852:0.004110:0.005065:0.009236:0.010360:0.005065:0.004110:0.002925:0.005819:0.004110:0.010360:0.004110:0.004680:0.009929:0.004904:0.014286:0.004110:0.009929:0.004680:0.004110:0.010391:0.008097:0.005819:0.004417:0.009852:0.010206:0.009206:0.002925:0.010360:0.005065:0.009852:0.010391:0.004110:0.002925:0.009236:0.003656:0.003656:0.010360:0.014286:0.014286:0.010360:0.005065:0.002925:0.009929:0.009236:0.004110:0.004110:0.006404:0.009236:0.009852:0.004110:0.005065:0.009852:0.004904:0.014286:0.004110:0.007512:0.003325:0.009190:0.007512:0.004110:0.009236:0.010360:0.005819:0.004110:0.004415:0.009929:0.009206:0.005065:0.002925:0.009236:0.009852:0.002925:0.008097:0.004110:0.010345:0.009852:0.009852:0.009387:0.004264
associated with both infectious processes (sepsis) and noninfectious insults, such as an autoimmune disorder, :@0.084855:0.312931:0.877990:0.312931:0.877990:0.298926:0.084855:0.298926:0.010360:0.005819:0.005819:0.009929:0.009806:0.002925:0.010360:0.005065:0.009852:0.010391:0.004110:0.012638:0.002925:0.005065:0.009236:0.004110:0.010345:0.009929:0.005065:0.009236:0.004110:0.002925:0.009236:0.004680:0.009852:0.009806:0.005065:0.002925:0.009929:0.009206:0.005819:0.004110:0.010345:0.004417:0.009929:0.009806:0.009852:0.005819:0.005819:0.009852:0.005819:0.004110:0.005526:0.005819:0.009852:0.010345:0.005819:0.002925:0.005819:0.005526:0.004110:0.010360:0.009236:0.010391:0.004110:0.009236:0.009929:0.009236:0.002925:0.009236:0.004680:0.009852:0.009806:0.005065:0.002925:0.009929:0.009206:0.005819:0.004110:0.002925:0.009236:0.005819:0.009206:0.002925:0.005065:0.005819:0.004110:0.004110:0.005819:0.009206:0.009806:0.009236:0.004110:0.010360:0.005819:0.004110:0.010360:0.009236:0.004110:0.010360:0.009206:0.005065:0.009929:0.002925:0.014286:0.014286:0.009206:0.009236:0.009852:0.004110:0.010391:0.002925:0.005819:0.009929:0.004387:0.010391:0.009852:0.002860:0.004263:0.004264
pancreatitis, vasculitis, thrombo-embolism, burns, or surgery. SIRS was previously defined as two or more :@0.084855:0.327630:0.839156:0.327630:0.839156:0.313625:0.084855:0.313625:0.010345:0.010360:0.009236:0.009806:0.004417:0.009852:0.010360:0.005065:0.002925:0.005065:0.002925:0.005819:0.004110:0.004110:0.008374:0.010360:0.005819:0.009806:0.009206:0.002925:0.002925:0.005065:0.002925:0.005819:0.004110:0.004110:0.005065:0.009236:0.004417:0.009929:0.014286:0.010345:0.009929:0.004957:0.009852:0.014286:0.010345:0.009929:0.002925:0.002925:0.005819:0.014286:0.004110:0.004110:0.010345:0.009206:0.004800:0.009236:0.005819:0.004110:0.004110:0.009929:0.004480:0.004110:0.005819:0.009206:0.004490:0.010206:0.009852:0.004480:0.008097:0.004110:0.004110:0.007512:0.003325:0.009190:0.007512:0.004110:0.012638:0.010360:0.005819:0.004110:0.010345:0.004415:0.009852:0.008374:0.002925:0.009929:0.009206:0.005819:0.002925:0.008097:0.004110:0.010391:0.009852:0.003671:0.003671:0.009236:0.009852:0.010391:0.004110:0.010360:0.005819:0.004110:0.005065:0.012638:0.009929:0.004110:0.009929:0.004480:0.004110:0.014286:0.009929:0.004417:0.010005:0.004264
abnormalities in temperature, heart rate, respiration, or white blood cell count.  However, in practice, its clinical :@0.084855:0.342329:0.898150:0.342333:0.898150:0.328328:0.084855:0.328324:0.010360:0.010345:0.009236:0.009929:0.004904:0.014286:0.010360:0.002925:0.002925:0.005065:0.002925:0.009852:0.005819:0.004110:0.002925:0.009236:0.004110:0.005065:0.009852:0.014286:0.010345:0.009852:0.004480:0.010360:0.005065:0.009206:0.004415:0.009852:0.004110:0.004110:0.009236:0.009852:0.010360:0.004480:0.005065:0.004110:0.004480:0.010360:0.005065:0.009852:0.004110:0.004110:0.004417:0.009852:0.005819:0.010345:0.002925:0.004480:0.010360:0.005065:0.002925:0.009929:0.009236:0.004110:0.004110:0.009929:0.004480:0.004110:0.012638:0.009236:0.002925:0.005065:0.009852:0.004110:0.010345:0.002925:0.009929:0.009929:0.010391:0.004110:0.009806:0.009852:0.002925:0.002925:0.004110:0.009806:0.009929:0.009206:0.009236:0.005065:0.004264:0.004663:0.004110:0.010360:0.009929:0.012638:0.009852:0.008374:0.009852:0.002860:0.004110:0.004110:0.002925:0.009236:0.004110:0.010345:0.004480:0.010360:0.009806:0.005065:0.002925:0.009806:0.009852:0.004110:0.004110:0.002925:0.005065:0.005819:0.004110:0.009806:0.002925:0.002925:0.009236:0.002925:0.009806:0.010360:0.003082:0.083091
3:@0.656693:0.337338:0.661665:0.337338:0.661665:0.329173:0.656693:0.329173:0.004972
definition and pathophysiology are nonequivocal such that SIRS and early sepsis cannot be readily distinguished. :@0.084843:0.357032:0.911400:0.357032:0.911400:0.343027:0.084843:0.343027:0.010391:0.009852:0.003671:0.003671:0.009236:0.002925:0.005065:0.002925:0.009929:0.009236:0.004110:0.010360:0.009236:0.010391:0.004110:0.010345:0.010360:0.005065:0.009236:0.009929:0.010345:0.009236:0.008097:0.005819:0.002925:0.009929:0.002925:0.009929:0.010206:0.008097:0.004110:0.010360:0.004417:0.009852:0.004110:0.009236:0.009929:0.009236:0.009852:0.010345:0.009206:0.002925:0.008374:0.009929:0.009806:0.010360:0.002925:0.004110:0.005819:0.009206:0.009806:0.009236:0.004110:0.005065:0.009236:0.010360:0.005065:0.004110:0.007512:0.003325:0.009190:0.007512:0.004110:0.010360:0.009236:0.010391:0.004110:0.009852:0.010360:0.004480:0.002925:0.008097:0.004110:0.005819:0.009852:0.010345:0.005819:0.002925:0.005819:0.004110:0.009806:0.010360:0.009236:0.009236:0.009929:0.005065:0.004110:0.010345:0.009852:0.004110:0.004417:0.009852:0.010360:0.010391:0.002925:0.002925:0.008097:0.004110:0.010391:0.002925:0.005819:0.005065:0.002925:0.009236:0.010206:0.009206:0.002925:0.005819:0.009236:0.009852:0.010391:0.004263:0.004264
Thus, when SIRS is suspected it should prompt an evaluation for a septic focus.:@0.084843:0.371731:0.651278:0.371731:0.651278:0.357726:0.084843:0.357726:0.006404:0.009236:0.009206:0.005819:0.004110:0.004110:0.012638:0.009236:0.009852:0.009236:0.004110:0.007512:0.003325:0.009190:0.007512:0.004110:0.002925:0.005819:0.004110:0.005819:0.009206:0.005819:0.010345:0.009852:0.009806:0.005065:0.009852:0.010391:0.004110:0.002925:0.005065:0.004110:0.005819:0.009236:0.009929:0.009206:0.002925:0.010391:0.004110:0.010345:0.004415:0.009929:0.014286:0.010345:0.005065:0.004110:0.010360:0.009236:0.004110:0.009852:0.008374:0.010360:0.002925:0.009206:0.010360:0.005065:0.002925:0.009929:0.009236:0.004110:0.004680:0.009929:0.004480:0.004110:0.010360:0.004110:0.005819:0.009852:0.010345:0.005065:0.002925:0.009806:0.004110:0.004680:0.009929:0.009806:0.009206:0.005976:0.004264
Δ:@0.084843:0.392239:0.094711:0.392239:0.094711:0.376376:0.084843:0.376376:0.009868
 Hypoperfusion is defined by hypotension persisting after initial fluid challenge or blood lactate concentration :@0.094711:0.390593:0.911291:0.390593:0.911291:0.376588:0.094711:0.376588:0.004264:0.010514:0.008251:0.010499:0.010083:0.010499:0.010006:0.005366:0.004834:0.009360:0.005973:0.003079:0.010083:0.009390:0.004264:0.003079:0.005973:0.004264:0.010545:0.010006:0.003748:0.003748:0.009390:0.010006:0.010545:0.004264:0.010499:0.008251:0.004264:0.009390:0.008251:0.010499:0.010083:0.005219:0.010006:0.009390:0.005973:0.003079:0.010083:0.009390:0.004264:0.010499:0.010006:0.004634:0.005973:0.003079:0.005973:0.005219:0.003079:0.009390:0.010360:0.004264:0.010514:0.004834:0.005219:0.010006:0.004634:0.004264:0.003079:0.009390:0.003079:0.005219:0.003079:0.010514:0.003079:0.004264:0.003733:0.003733:0.009360:0.003079:0.010545:0.004264:0.009960:0.009390:0.010514:0.003079:0.003079:0.010006:0.009390:0.010360:0.010006:0.004264:0.010083:0.004634:0.004264:0.010499:0.003079:0.010083:0.010083:0.010545:0.004264:0.003079:0.010514:0.009960:0.005219:0.010514:0.005219:0.010006:0.004264:0.009960:0.010083:0.009390:0.009960:0.010006:0.009390:0.005219:0.004634:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264
≥4 mmol/L.  Refer to the UpToDate topic review on the definition of sepsis and SIRS for additional details.:@0.084843:0.405292:0.855322:0.405296:0.855322:0.391291:0.084843:0.391287:0.008451:0.008528:0.004264:0.014439:0.014439:0.010083:0.003079:0.006727:0.007112:0.004264:0.004973:0.004264:0.009344:0.010006:0.004834:0.010006:0.004634:0.004264:0.005219:0.010083:0.004264:0.005219:0.009390:0.010006:0.004264:0.010083:0.010499:0.005802:0.010083:0.011453:0.010514:0.005219:0.010006:0.004264:0.005219:0.010083:0.010499:0.003079:0.009960:0.004264:0.004570:0.010006:0.008528:0.003079:0.010006:0.012792:0.004264:0.010083:0.009390:0.004264:0.005219:0.009390:0.010006:0.004264:0.010545:0.010006:0.003748:0.003748:0.009390:0.003079:0.005219:0.003079:0.010083:0.009390:0.004264:0.010083:0.004834:0.004264:0.005973:0.010006:0.010499:0.005973:0.003079:0.005973:0.004264:0.010514:0.009390:0.010545:0.004264:0.007666:0.003479:0.009344:0.007666:0.004264:0.004834:0.010083:0.004634:0.004264:0.010514:0.010545:0.010545:0.003079:0.005219:0.003079:0.010083:0.009390:0.010514:0.003079:0.004264:0.010545:0.010006:0.005219:0.010514:0.003079:0.003079:0.005973:0.034336
4:@0.166230:0.400301:0.171202:0.400301:0.171202:0.392136:0.166230:0.392136:0.004972
◊:@0.084844:0.425804:0.093403:0.425804:0.093403:0.409941:0.084844:0.409941:0.008559
 Goal-directed therapy for initial resuscitation includes the following: (a) central venous pressure 8 to 12 :@0.093403:0.424158:0.862599:0.424158:0.862599:0.410153:0.093403:0.410153:0.004264:0.013424:0.010083:0.010514:0.003079:0.005111:0.010545:0.003079:0.004569:0.010006:0.009960:0.005219:0.010006:0.010545:0.004264:0.005219:0.009390:0.010006:0.004634:0.010514:0.010499:0.008251:0.004264:0.004834:0.010083:0.004634:0.004264:0.003079:0.009390:0.003079:0.005219:0.003079:0.010514:0.003079:0.004264:0.004570:0.010006:0.005973:0.009360:0.005973:0.009960:0.003079:0.005219:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264:0.003079:0.009390:0.009960:0.003079:0.009360:0.010545:0.010006:0.005973:0.004264:0.005219:0.009390:0.010006:0.004264:0.004834:0.010083:0.003079:0.003079:0.010083:0.012792:0.003079:0.009390:0.010360:0.004264:0.004264:0.005680:0.010514:0.005680:0.004264:0.009960:0.010006:0.009390:0.005219:0.004634:0.010514:0.003079:0.004264:0.008528:0.010006:0.009390:0.010083:0.009360:0.005973:0.004264:0.010499:0.004570:0.010006:0.005973:0.005973:0.009360:0.004570:0.010006:0.004264:0.008528:0.004264:0.005219:0.010083:0.004264:0.008528:0.008528:0.004264
mmHg; (b) mean arterial pressure ≥65 mmHg; (c) urine output ≥0.5 mL/kg per hour; and (d) central venous :@0.084844:0.438857:0.879012:0.438857:0.879012:0.424852:0.084844:0.424852:0.014439:0.014439:0.010514:0.010360:0.004264:0.004264:0.005680:0.010499:0.005680:0.004264:0.014439:0.010006:0.010514:0.009390:0.004264:0.010514:0.004634:0.005219:0.010006:0.004634:0.003079:0.010514:0.003079:0.004264:0.010499:0.004570:0.010006:0.005973:0.005973:0.009360:0.004569:0.010006:0.004264:0.008451:0.008528:0.008528:0.004264:0.014439:0.014439:0.010514:0.010360:0.004264:0.004264:0.005680:0.009960:0.005680:0.004264:0.009360:0.004634:0.003079:0.009390:0.010006:0.004264:0.010083:0.009360:0.005219:0.010499:0.009360:0.005219:0.004264:0.008451:0.008528:0.004264:0.008528:0.004264:0.014439:0.007112:0.006727:0.007728:0.010360:0.004264:0.010499:0.010006:0.004634:0.004264:0.009390:0.010083:0.009360:0.004634:0.004264:0.004264:0.010514:0.009390:0.010545:0.004264:0.005680:0.010545:0.005680:0.004264:0.009960:0.010006:0.009390:0.005219:0.004634:0.010514:0.003079:0.004264:0.008528:0.010006:0.009390:0.010083:0.009360:0.005973:0.004264
(superior vena cava) oxygen saturation ≥70 percent or mixed venous oxygen saturation ≥65 percent.  Refer to :@0.084844:0.453556:0.906620:0.453560:0.906620:0.439555:0.084844:0.439551:0.005680:0.005973:0.009360:0.010499:0.010006:0.004634:0.003079:0.010083:0.004634:0.004264:0.008528:0.010006:0.009390:0.010514:0.004264:0.009960:0.010514:0.008528:0.010514:0.005680:0.004264:0.010083:0.007389:0.008251:0.010360:0.010006:0.009390:0.004264:0.005973:0.010514:0.005219:0.009360:0.004634:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264:0.008451:0.008528:0.008528:0.004264:0.010499:0.010006:0.004526:0.009960:0.010006:0.009390:0.005219:0.004264:0.010083:0.004634:0.004264:0.014439:0.003079:0.007389:0.010006:0.010545:0.004264:0.008528:0.010006:0.009390:0.010083:0.009360:0.005973:0.004264:0.010083:0.007389:0.008251:0.010360:0.010006:0.009390:0.004264:0.005973:0.010514:0.005219:0.009360:0.004634:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264:0.008451:0.008528:0.008528:0.004264:0.010499:0.010006:0.004524:0.009960:0.010006:0.009390:0.005219:0.004264:0.004915:0.004264:0.009344:0.010006:0.004834:0.010006:0.004634:0.004264:0.005219:0.010083:-0.087163
4:@0.834729:0.448565:0.839701:0.448565:0.839701:0.440400:0.834729:0.440400:0.004972
the UpToDate topic review on evaluation and management of sepsis for additional details.:@0.084846:0.468259:0.760776:0.468259:0.760776:0.454254:0.084846:0.454254:0.005219:0.009390:0.010006:0.004264:0.010083:0.010499:0.005804:0.010083:0.011453:0.010514:0.005219:0.010006:0.004264:0.005219:0.010083:0.010499:0.003079:0.009960:0.004264:0.004570:0.010006:0.008528:0.003079:0.010006:0.012792:0.004264:0.010083:0.009390:0.004264:0.010006:0.008528:0.010514:0.003079:0.009360:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264:0.010514:0.009390:0.010545:0.004264:0.014439:0.010514:0.009390:0.010514:0.010360:0.010006:0.014439:0.010006:0.009390:0.005219:0.004264:0.010083:0.004834:0.004264:0.005973:0.010006:0.010499:0.005973:0.003079:0.005973:0.004264:0.004834:0.010083:0.004634:0.004264:0.010514:0.010545:0.010545:0.003079:0.005219:0.003079:0.010083:0.009390:0.010514:0.003079:0.004264:0.010545:0.010006:0.005219:0.010514:0.003079:0.003079:0.005973:0.004264
§:@0.084846:0.488767:0.092189:0.488767:0.092189:0.472904:0.084846:0.472904:0.007343
 Sepsis is defined as the presence (probable or documented) of infection together with systemic :@0.092189:0.487121:0.811526:0.487121:0.811526:0.473116:0.092189:0.473116:0.004264:0.007666:0.010006:0.010499:0.005973:0.003079:0.005973:0.004264:0.003079:0.005973:0.004264:0.010545:0.010006:0.003748:0.003748:0.009390:0.010006:0.010545:0.004264:0.010514:0.005973:0.004264:0.005219:0.009390:0.010006:0.004264:0.010499:0.004569:0.010006:0.005973:0.010006:0.009390:0.009960:0.010006:0.004264:0.005680:0.010499:0.004569:0.010083:0.010499:0.010514:0.010499:0.003079:0.010006:0.004264:0.010083:0.004634:0.004264:0.010545:0.010083:0.009960:0.009360:0.014439:0.010006:0.009390:0.005219:0.010006:0.010545:0.005680:0.004264:0.010083:0.004834:0.004264:0.003079:0.009390:0.004834:0.010006:0.009960:0.005219:0.003079:0.010083:0.009390:0.004264:0.005219:0.010083:0.010360:0.010006:0.005219:0.009390:0.010006:0.004634:0.004264:0.012792:0.003079:0.005219:0.009390:0.004264:0.005973:0.008251:0.005973:0.005219:0.010006:0.014439:0.003079:0.009960:0.004264
manifestations of infection (eg, temperature >38.3 or <36°C, heart rate >90 beats/min, respiratory rate >20 :@0.084846:0.501820:0.875319:0.501820:0.875319:0.487815:0.084846:0.487815:0.014439:0.010514:0.009390:0.003079:0.004834:0.010006:0.005973:0.005219:0.010514:0.005219:0.003079:0.010083:0.009390:0.005973:0.004264:0.010083:0.004834:0.004264:0.003079:0.009390:0.004834:0.010006:0.009960:0.005219:0.003079:0.010083:0.009390:0.004264:0.005680:0.010006:0.010360:0.004264:0.004264:0.005219:0.010006:0.014439:0.010499:0.010006:0.004634:0.010514:0.005219:0.009360:0.004570:0.010006:0.004264:0.009329:0.008528:0.008528:0.004264:0.008528:0.004264:0.010083:0.004634:0.004264:0.009329:0.008528:0.008528:0.006158:0.012515:0.004264:0.004264:0.009390:0.010006:0.010514:0.004634:0.005219:0.004264:0.004634:0.010514:0.005219:0.010006:0.004264:0.009329:0.008528:0.008528:0.004264:0.010499:0.010006:0.010514:0.005219:0.005973:0.006727:0.014439:0.003079:0.009390:0.004264:0.004264:0.004569:0.010006:0.005973:0.010499:0.003079:0.004634:0.010514:0.005219:0.010083:0.004634:0.008251:0.004264:0.004634:0.010514:0.005219:0.010006:0.004264:0.009329:0.008528:0.008528:0.004264
breaths/min, altered mental status, leukocytosis, arterial hypotension, arterial hypoxaemia).  Refer to the :@0.084846:0.516519:0.863024:0.516523:0.863024:0.502518:0.084846:0.502514:0.010499:0.004570:0.010006:0.010514:0.005219:0.009390:0.005973:0.006727:0.014439:0.003079:0.009390:0.004264:0.004264:0.010514:0.003079:0.005219:0.010006:0.004570:0.010006:0.010545:0.004264:0.014439:0.010006:0.009390:0.005219:0.010514:0.003079:0.004264:0.005973:0.005219:0.010514:0.005219:0.009360:0.005973:0.004264:0.004264:0.003079:0.010006:0.009360:0.007728:0.010083:0.009960:0.008251:0.005219:0.010083:0.005973:0.003079:0.005973:0.004264:0.004264:0.010514:0.004634:0.005219:0.010006:0.004634:0.003079:0.010514:0.003079:0.004264:0.009390:0.008251:0.010499:0.010083:0.005219:0.010006:0.009390:0.005973:0.003079:0.010083:0.009390:0.004264:0.004264:0.010514:0.004634:0.005219:0.010006:0.004634:0.003079:0.010514:0.003079:0.004264:0.009390:0.008251:0.010499:0.010083:0.007389:0.010514:0.010006:0.014439:0.003079:0.010514:0.005680:0.004264:0.004944:0.004264:0.009344:0.010006:0.004834:0.010006:0.004634:0.004264:0.005219:0.010083:0.004264:0.005219:0.009390:0.010006:-0.135150
4:@0.762254:0.511528:0.767226:0.511528:0.767226:0.503363:0.762254:0.503363:0.004972
UpToDate topic review on the definition of sepsis and SIRS for the full diagnostic criteria for sepsis.:@0.084846:0.531222:0.801109:0.531222:0.801109:0.517217:0.084846:0.517217:0.010083:0.010499:0.005804:0.010083:0.011453:0.010514:0.005219:0.010006:0.004264:0.005219:0.010083:0.010499:0.003079:0.009960:0.004264:0.004570:0.010006:0.008528:0.003079:0.010006:0.012792:0.004264:0.010083:0.009390:0.004264:0.005219:0.009390:0.010006:0.004264:0.010545:0.010006:0.003748:0.003748:0.009390:0.003079:0.005219:0.003079:0.010083:0.009390:0.004264:0.010083:0.004834:0.004264:0.005973:0.010006:0.010499:0.005973:0.003079:0.005973:0.004264:0.010514:0.009390:0.010545:0.004264:0.007666:0.003479:0.009344:0.007666:0.004264:0.004834:0.010083:0.004634:0.004264:0.005219:0.009390:0.010006:0.004264:0.004834:0.009360:0.003079:0.003079:0.004264:0.010545:0.003079:0.010514:0.010360:0.009390:0.010083:0.005973:0.005219:0.003079:0.009960:0.004264:0.009960:0.004634:0.003079:0.005219:0.010006:0.004634:0.003079:0.010514:0.004264:0.004834:0.010083:0.004634:0.004264:0.005973:0.010006:0.010499:0.005973:0.003079:0.005973:0.004264
¥ Patients at low risk for serious complications are defined as those who are expected to be neutropaenic :@0.084846:0.550084:0.874858:0.550084:0.874858:0.536078:0.084846:0.536078:0.008528:0.004264:0.009113:0.010514:0.005219:0.003079:0.010006:0.009390:0.005219:0.005973:0.004264:0.010514:0.005219:0.004264:0.003079:0.010083:0.012792:0.004264:0.004634:0.003079:0.005973:0.007728:0.004264:0.004834:0.010083:0.004634:0.004264:0.005973:0.010006:0.004634:0.003079:0.010083:0.009360:0.005973:0.004264:0.009960:0.010083:0.014439:0.010499:0.003079:0.003079:0.009960:0.010514:0.005219:0.003079:0.010083:0.009390:0.005973:0.004264:0.010514:0.004570:0.010006:0.004264:0.010545:0.010006:0.003748:0.003748:0.009390:0.010006:0.010545:0.004264:0.010514:0.005973:0.004264:0.005219:0.009390:0.010083:0.005973:0.010006:0.004264:0.012792:0.009390:0.010083:0.004264:0.010514:0.004570:0.010006:0.004264:0.010006:0.007389:0.010499:0.010006:0.009960:0.005219:0.010006:0.010545:0.004264:0.005219:0.010083:0.004264:0.010499:0.010006:0.004264:0.009390:0.010006:0.009360:0.005219:0.004570:0.010083:0.010499:0.010514:0.010006:0.009390:0.003079:0.009960:0.004264
(absolute neutrophil count [ANC] <500 cells/microL) for ≤7 days and those with no comorbidities or evidence :@0.084846:0.564783:0.896734:0.564783:0.896734:0.550778:0.084846:0.550778:0.005680:0.010514:0.010499:0.005973:0.010083:0.003079:0.009360:0.005219:0.010006:0.004264:0.009390:0.010006:0.009360:0.005219:0.004570:0.010083:0.010499:0.009390:0.003079:0.003079:0.004264:0.009960:0.010083:0.009360:0.009390:0.005219:0.004264:0.005403:0.011392:0.011392:0.012515:0.005403:0.004264:0.009329:0.008528:0.008528:0.008528:0.004264:0.009960:0.010006:0.003079:0.003079:0.005973:0.006727:0.014439:0.003079:0.009960:0.004570:0.010083:0.007112:0.005680:0.004264:0.004834:0.010083:0.004634:0.004264:0.008451:0.008528:0.004264:0.010545:0.010514:0.008251:0.005973:0.004264:0.010514:0.009390:0.010545:0.004264:0.005219:0.009390:0.010083:0.005973:0.010006:0.004264:0.012792:0.003079:0.005219:0.009390:0.004264:0.009390:0.010083:0.004264:0.009960:0.010083:0.014439:0.010083:0.004634:0.010499:0.003079:0.010545:0.003079:0.005219:0.003079:0.010006:0.005973:0.004264:0.010083:0.004634:0.004264:0.010006:0.008528:0.003079:0.010545:0.010006:0.009390:0.009960:0.010006:0.004264
of significant hepatic or renal dysfunction. High-risk patients are defined as those who are expected to be :@0.084846:0.579482:0.874795:0.579482:0.874795:0.565477:0.084846:0.565477:0.010083:0.004834:0.004264:0.005973:0.003079:0.010360:0.009390:0.003079:0.003748:0.003748:0.009960:0.010514:0.009390:0.005219:0.004264:0.009390:0.010006:0.010499:0.010514:0.005219:0.003079:0.009960:0.004264:0.010083:0.004634:0.004264:0.004569:0.010006:0.009390:0.010514:0.003079:0.004264:0.010545:0.008251:0.005973:0.004834:0.009360:0.009390:0.009960:0.005219:0.003079:0.010083:0.009390:0.004264:0.004264:0.010514:0.003079:0.010360:0.009390:0.005111:0.004634:0.003079:0.005973:0.007728:0.004264:0.010499:0.010514:0.005219:0.003079:0.010006:0.009390:0.005219:0.005973:0.004264:0.010514:0.004570:0.010006:0.004264:0.010545:0.010006:0.003748:0.003748:0.009390:0.010006:0.010545:0.004264:0.010514:0.005973:0.004264:0.005219:0.009390:0.010083:0.005973:0.010006:0.004264:0.012792:0.009390:0.010083:0.004264:0.010514:0.004570:0.010006:0.004264:0.010006:0.007389:0.010499:0.010006:0.009960:0.005219:0.010006:0.010545:0.004264:0.005219:0.010083:0.004264:0.010499:0.010006:0.004264
neutropaenic (ANC <500 cells/microL) for >7 days; patients with neutropaenic fever who have ongoing :@0.084846:0.594181:0.857124:0.594181:0.857124:0.580176:0.084846:0.580176:0.009390:0.010006:0.009360:0.005219:0.004570:0.010083:0.010499:0.010514:0.010006:0.009390:0.003079:0.009960:0.004264:0.005680:0.011392:0.011392:0.012515:0.004264:0.009329:0.008528:0.008528:0.008528:0.004264:0.009960:0.010006:0.003079:0.003079:0.005973:0.006727:0.014439:0.003079:0.009960:0.004570:0.010083:0.007112:0.005680:0.004264:0.004834:0.010083:0.004634:0.004264:0.009329:0.008528:0.004264:0.010545:0.010514:0.008251:0.005973:0.004264:0.004264:0.010499:0.010514:0.005219:0.003079:0.010006:0.009390:0.005219:0.005973:0.004264:0.012792:0.003079:0.005219:0.009390:0.004264:0.009390:0.010006:0.009360:0.005219:0.004570:0.010083:0.010499:0.010514:0.010006:0.009390:0.003079:0.009960:0.004264:0.004834:0.010006:0.008528:0.010006:0.004634:0.004264:0.012792:0.009390:0.010083:0.004264:0.009390:0.010514:0.008528:0.010006:0.004264:0.010083:0.009390:0.010360:0.010083:0.003079:0.009390:0.010360:0.004264
comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high risk, :@0.084846:0.608880:0.858987:0.608880:0.858987:0.594875:0.084846:0.594875:0.009960:0.010083:0.014439:0.010083:0.004634:0.010499:0.003079:0.010545:0.003079:0.005219:0.003079:0.010006:0.005973:0.004264:0.010083:0.004634:0.004264:0.010006:0.008528:0.003079:0.010545:0.010006:0.009390:0.009960:0.010006:0.004264:0.010083:0.004834:0.004264:0.005973:0.003079:0.010360:0.009390:0.003079:0.003748:0.003748:0.009960:0.010514:0.009390:0.005219:0.004264:0.009390:0.010006:0.010499:0.010514:0.005219:0.003079:0.009960:0.004264:0.010083:0.004634:0.004264:0.004570:0.010006:0.009390:0.010514:0.003079:0.004264:0.010545:0.008251:0.005973:0.004834:0.009360:0.009390:0.009960:0.005219:0.003079:0.010083:0.009390:0.004264:0.010514:0.004570:0.010006:0.004264:0.010514:0.003079:0.005973:0.010083:0.004264:0.009960:0.010083:0.009390:0.005973:0.003079:0.010545:0.010006:0.004570:0.010006:0.010545:0.004264:0.005219:0.010083:0.004264:0.010499:0.010006:0.004264:0.009390:0.003079:0.010360:0.009390:0.004264:0.004634:0.003079:0.005973:0.007728:0.004264:0.004264
regardless of the duration of neutropaenia. The Multinational Association for Supportive Care in Cancer :@0.084846:0.623579:0.857338:0.623579:0.857338:0.609574:0.084846:0.609574:0.004570:0.010006:0.010360:0.010514:0.004540:0.010545:0.003079:0.010006:0.005973:0.005973:0.004264:0.010083:0.004834:0.004264:0.005219:0.009390:0.010006:0.004264:0.010545:0.009360:0.004634:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264:0.010083:0.004834:0.004264:0.009390:0.010006:0.009360:0.005219:0.004570:0.010083:0.010499:0.010514:0.010006:0.009390:0.003079:0.010514:0.004264:0.004264:0.006558:0.009390:0.010006:0.004264:0.014147:0.009360:0.003079:0.005219:0.003079:0.009390:0.010514:0.005219:0.003079:0.010083:0.009390:0.010514:0.003079:0.004264:0.011392:0.005973:0.005973:0.010083:0.009960:0.003079:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264:0.004834:0.010083:0.004634:0.004264:0.007666:0.009360:0.010499:0.010499:0.010083:0.004634:0.005219:0.003079:0.008528:0.010006:0.004264:0.012515:0.010514:0.004570:0.010006:0.004264:0.003079:0.009390:0.004264:0.012515:0.010514:0.009390:0.009960:0.010006:0.004634:0.004264
(MASCC) risk index can also be used for determining risk. A MASCC score of ≥21 predicts a low risk for medical :@0.084846:0.638278:0.907057:0.638278:0.907057:0.624273:0.084846:0.624273:0.005680:0.014147:0.011392:0.007666:0.012515:0.012515:0.005680:0.004264:0.004634:0.003079:0.005973:0.007728:0.004264:0.003079:0.009390:0.010545:0.010006:0.007389:0.004264:0.009960:0.010514:0.009390:0.004264:0.010514:0.003079:0.005973:0.010083:0.004264:0.010499:0.010006:0.004264:0.009360:0.005973:0.010006:0.010545:0.004264:0.004834:0.010083:0.004634:0.004264:0.010545:0.010006:0.005219:0.010006:0.005060:0.014439:0.003079:0.009390:0.003079:0.009390:0.010360:0.004264:0.004634:0.003079:0.005973:0.007728:0.004264:0.004264:0.011392:0.004264:0.014147:0.011392:0.007666:0.012515:0.012515:0.004264:0.005973:0.009960:0.010083:0.004569:0.010006:0.004264:0.010083:0.004834:0.004264:0.008451:0.008528:0.008528:0.004264:0.010499:0.004570:0.010006:0.010545:0.003079:0.009960:0.005219:0.005973:0.004264:0.010514:0.004264:0.003079:0.010083:0.012792:0.004264:0.004634:0.003079:0.005973:0.007728:0.004264:0.004834:0.010083:0.004634:0.004264:0.014439:0.010006:0.010545:0.003079:0.009960:0.010514:0.003079:0.004264
complications of neutropaenic fever syndromes that would require hospitalisation and/or prolonged length of :@0.084846:0.652977:0.906195:0.652977:0.906195:0.638972:0.084846:0.638972:0.009960:0.010083:0.014439:0.010499:0.003079:0.003079:0.009960:0.010514:0.005219:0.003079:0.010083:0.009390:0.005973:0.004264:0.010083:0.004834:0.004264:0.009390:0.010006:0.009360:0.005219:0.004570:0.010083:0.010499:0.010514:0.010006:0.009390:0.003079:0.009960:0.004264:0.004834:0.010006:0.008528:0.010006:0.004634:0.004264:0.005973:0.008251:0.009390:0.010545:0.004570:0.010083:0.014439:0.010006:0.005973:0.004264:0.005219:0.009390:0.010514:0.005219:0.004264:0.012792:0.010083:0.009360:0.003079:0.010545:0.004264:0.004570:0.010006:0.010499:0.009360:0.003079:0.004570:0.010006:0.004264:0.009390:0.010083:0.005973:0.010499:0.003079:0.005219:0.010514:0.003079:0.003079:0.005973:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264:0.010514:0.009390:0.010545:0.006727:0.010083:0.004634:0.004264:0.010499:0.004569:0.010083:0.003079:0.010083:0.009390:0.010360:0.010006:0.010545:0.004264:0.003079:0.010006:0.009390:0.010360:0.005219:0.009390:0.004264:0.010083:0.004834:0.004264
hospitalisation. A score of <21 predicts patients at high risk for such complications.  Refer to the text for more :@0.084846:0.667676:0.891718:0.667680:0.891718:0.653675:0.084846:0.653671:0.009390:0.010083:0.005973:0.010499:0.003079:0.005219:0.010514:0.003079:0.003079:0.005973:0.010514:0.005219:0.003079:0.010083:0.009390:0.004264:0.004264:0.011392:0.004264:0.005973:0.009960:0.010083:0.004570:0.010006:0.004264:0.010083:0.004834:0.004264:0.009329:0.008528:0.008528:0.004264:0.010499:0.004570:0.010006:0.010545:0.003079:0.009960:0.005219:0.005973:0.004264:0.010499:0.010514:0.005219:0.003079:0.010006:0.009390:0.005219:0.005973:0.004264:0.010514:0.005219:0.004264:0.009390:0.003079:0.010360:0.009390:0.004264:0.004634:0.003079:0.005973:0.007728:0.004264:0.004834:0.010083:0.004634:0.004264:0.005973:0.009360:0.009960:0.009390:0.004264:0.009960:0.010083:0.014439:0.010499:0.003079:0.003079:0.009960:0.010514:0.005219:0.003079:0.010083:0.009390:0.005973:0.004264:0.004945:0.004264:0.009344:0.010006:0.004834:0.010006:0.004634:0.004264:0.005219:0.010083:0.004264:0.005219:0.009390:0.010006:0.004264:0.005219:0.010006:0.007389:0.005219:0.004264:0.004834:0.010083:0.004634:0.004264:0.014439:0.010083:0.004570:0.010006:-0.383709
5:@0.691674:0.662686:0.696646:0.662686:0.696646:0.654521:0.691674:0.654521:0.004972
details regarding the definitions of low- and high-risk patients based upon clinical criteria and the MASCC risk :@0.084847:0.682379:0.897903:0.682379:0.897903:0.668374:0.084847:0.668374:0.010545:0.010006:0.005219:0.010514:0.003079:0.003079:0.005973:0.004264:0.004569:0.010006:0.010360:0.010514:0.004540:0.010545:0.003079:0.009390:0.010360:0.004264:0.005219:0.009390:0.010006:0.004264:0.010545:0.010006:0.003748:0.003748:0.009390:0.003079:0.005219:0.003079:0.010083:0.009390:0.005973:0.004264:0.010083:0.004834:0.004264:0.003079:0.010083:0.012792:0.005111:0.004264:0.010514:0.009390:0.010545:0.004264:0.009390:0.003079:0.010360:0.009390:0.005111:0.004634:0.003079:0.005973:0.007728:0.004264:0.010499:0.010514:0.005219:0.003079:0.010006:0.009390:0.005219:0.005973:0.004264:0.010499:0.010514:0.005973:0.010006:0.010545:0.004264:0.009360:0.010499:0.010083:0.009390:0.004264:0.009960:0.003079:0.003079:0.009390:0.003079:0.009960:0.010514:0.003079:0.004264:0.009960:0.004634:0.003079:0.005219:0.010006:0.004634:0.003079:0.010514:0.004264:0.010514:0.009390:0.010545:0.004264:0.005219:0.009390:0.010006:0.004264:0.014147:0.011392:0.007666:0.012515:0.012515:0.004264:0.004634:0.003079:0.005973:0.007728:0.004264
score.:@0.084847:0.697078:0.129703:0.697078:0.129703:0.683073:0.084847:0.683073:0.005973:0.009960:0.010083:0.004570:0.010006:0.004264
REFERENCES:@0.084848:0.730805:0.179059:0.730805:0.179059:0.715662:0.084848:0.715662:0.009487:0.008505:0.007851:0.008505:0.009487:0.008505:0.012103:0.012758:0.008505:0.008505
1.:@0.084848:0.744754:0.099062:0.744754:0.099062:0.730749:0.084848:0.730749:0.009476:0.004738
  Bell MS, Scullen P, McParlan D, :@0.121195:0.744754:0.385156:0.744754:0.385156:0.730749:0.121195:0.730749:0.004738:-0.004738:0.009818:0.011118:0.003421:0.003421:0.006927:0.015719:0.008518:0.004738:0.006910:0.008518:0.011067:0.010399:0.003421:0.003421:0.011118:0.010434:0.006927:0.008019:0.004738:0.006915:0.015719:0.011067:0.010126:0.011682:0.005148:0.003421:0.011682:0.010434:0.006915:0.012726:0.004738:0.004738
et al.:@0.387339:0.744754:0.431010:0.744754:0.431010:0.730749:0.387339:0.730749:0.011118:0.005798:0.006914:0.011682:0.003421:0.004738
 Neutropenic Sepsis Guideline. In Edition Northern Ireland:@0.431010:0.744754:0.915147:0.744754:0.915147:0.730749:0.431010:0.730749:0.006919:0.012657:0.011118:0.010399:0.005798:0.005068:0.011203:0.011665:0.011118:0.010434:0.003421:0.011067:0.006915:0.008518:0.011118:0.011665:0.006636:0.003421:0.006636:0.006927:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.004738:0.006917:0.003866:0.010434:0.006917:0.009168:0.011716:0.003421:0.005798:0.003421:0.011203:0.010434:0.006927:0.012657:0.011203:0.005148:0.005798:0.010434:0.011118:0.005485:0.010434:0.006917:0.003866:0.005078:0.011118:0.003421:0.011682:0.010434:0.011716
Cancer Network 2010;1-11.:@0.121195:0.758865:0.344236:0.758865:0.344236:0.744860:0.121195:0.744860:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.012657:0.011118:0.005798:0.014214:0.011203:0.005148:0.008586:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.005679:0.009476:0.009476:0.004738
2.:@0.084848:0.772976:0.099062:0.772976:0.099062:0.758971:0.084848:0.758971:0.009476:0.004738
  McKenzie  H, Hayes L,  White  K, :@0.121195:0.772976:0.384481:0.772976:0.384481:0.758971:0.121195:0.758971:0.004738:-0.004738:0.015719:0.011067:0.010109:0.011118:0.010434:0.007269:0.003421:0.011118:0.004738:0.002634:0.011682:0.004738:0.007389:0.011682:0.011682:0.009168:0.011118:0.006636:0.007389:0.007902:0.004738:0.004738:0.002641:0.016420:0.010434:0.003421:0.005798:0.011118:0.004738:0.002643:0.010109:0.004738:0.004738
et  al.:@0.387117:0.772976:0.431253:0.772976:0.431253:0.758971:0.387117:0.758971:0.011118:0.005798:0.004738:0.002641:0.011682:0.003421:0.004738
 Chemotherapy  outpatients’ unplanned  presentations  to:@0.431253:0.772976:0.915166:0.772976:0.915166:0.758971:0.431253:0.758971:0.007389:0.013906:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.002632:0.011203:0.010399:0.005798:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.006004:0.007389:0.010399:0.010434:0.011665:0.003421:0.011682:0.010434:0.010434:0.011118:0.011716:0.004738:0.002643:0.011665:0.005080:0.011118:0.006636:0.011118:0.010434:0.005798:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.002641:0.005798:0.011203
hospital: a retrospective study. :@0.121195:0.787088:0.377855:0.787088:0.377855:0.773082:0.121195:0.773082:0.010434:0.011203:0.006636:0.011665:0.003421:0.005798:0.011682:0.003421:0.004738:0.004738:0.011682:0.004738:0.005078:0.011118:0.005798:0.005073:0.011203:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.004738:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
Support Care Cancer.:@0.377855:0.787088:0.561675:0.787088:0.561675:0.773082:0.377855:0.773082:0.008518:0.010399:0.011665:0.011665:0.011203:0.005148:0.005798:0.004738:0.013906:0.011682:0.005148:0.011118:0.004738:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
 2011;19:963-969.:@0.561649:0.787088:0.699990:0.787088:0.699990:0.773082:0.561649:0.773082:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
3.:@0.084848:0.801199:0.099062:0.801199:0.099062:0.787193:0.084848:0.787193:0.009476:0.004738
  Levy MM, Fink MP, Marshall JC, :@0.121195:0.801199:0.376939:0.801199:0.376939:0.787193:0.121195:0.787193:0.004738:-0.004738:0.007902:0.011118:0.009476:0.009168:0.004584:0.015719:0.015719:0.004738:0.004584:0.008296:0.003421:0.010434:0.008586:0.004584:0.015719:0.008022:0.004738:0.004584:0.015719:0.011682:0.005148:0.006636:0.010434:0.011682:0.003421:0.003421:0.004584:0.008244:0.013906:0.004738:0.004738
et al. :@0.376786:0.801199:0.422865:0.801199:0.422865:0.787193:0.376786:0.787193:0.011118:0.005798:0.004584:0.011682:0.003421:0.004738:0.004738
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Defini-:@0.422711:0.801199:0.915159:0.801199:0.915159:0.787193:0.422711:0.787193:0.009476:0.009476:0.009476:0.009476:0.004598:0.008518:0.013906:0.013906:0.015719:0.007475:0.009168:0.008518:0.003866:0.013906:0.015719:0.007475:0.012657:0.013906:0.013906:0.010126:0.007475:0.011267:0.007286:0.008518:0.007475:0.008518:0.003866:0.008518:0.004586:0.003866:0.010434:0.005798:0.011118:0.005497:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004586:0.008518:0.011118:0.011665:0.006636:0.003421:0.006636:0.004596:0.012726:0.011118:0.004165:0.004165:0.010434:0.003421:0.005679
tions Conference. :@0.121195:0.815310:0.273733:0.815310:0.273733:0.801305:0.121195:0.801305:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.013906:0.011203:0.010434:0.005371:0.011118:0.005065:0.011118:0.010434:0.011067:0.011118:0.004738:0.004738
Intensive Care Med.:@0.273715:0.815310:0.440636:0.815310:0.440636:0.801305:0.273715:0.801305:0.003866:0.010434:0.005798:0.011118:0.010434:0.006636:0.003421:0.009476:0.011118:0.004738:0.013906:0.011682:0.005148:0.011118:0.004738:0.015719:0.011118:0.011716:0.004738
 2003;29:530.:@0.440619:0.815310:0.544853:0.815310:0.544853:0.801305:0.440619:0.801305:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738
4.:@0.084831:0.829421:0.099045:0.829421:0.099045:0.815416:0.084831:0.815416:0.009476:0.004738
  Dellinger RP, Levy MM, Rhodes A, :@0.121178:0.829421:0.408565:0.829421:0.408565:0.815416:0.121178:0.815416:0.004738:-0.004738:0.012726:0.011118:0.003421:0.003421:0.003421:0.010434:0.011511:0.011118:0.005148:0.006893:0.010382:0.008022:0.004738:0.006893:0.007902:0.011118:0.009476:0.009168:0.006893:0.015719:0.015719:0.004738:0.006893:0.010382:0.010434:0.011203:0.011716:0.011118:0.006636:0.006893:0.012657:0.004738:0.004738
et al.:@0.410721:0.829421:0.454371:0.829421:0.454371:0.815416:0.410721:0.815416:0.011118:0.005798:0.006893:0.011682:0.003421:0.004738
 Surviving sepsis campaign: international guidelines for:@0.454371:0.829421:0.915168:0.829421:0.915168:0.815416:0.454371:0.815416:0.006893:0.008518:0.010399:0.005148:0.009476:0.003421:0.009476:0.003421:0.010434:0.011511:0.006893:0.006636:0.011118:0.011665:0.006636:0.003421:0.006636:0.006905:0.011067:0.011682:0.016044:0.011665:0.011682:0.003421:0.011511:0.010434:0.004738:0.006893:0.003421:0.010434:0.005798:0.011118:0.005501:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.006893:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.006893:0.005371:0.011203:0.005148
management of severe sepsis and septic shock: 2012. :@0.121178:0.843532:0.571006:0.843532:0.571006:0.829527:0.121178:0.829527:0.016044:0.011682:0.010434:0.011682:0.011511:0.011118:0.016044:0.011118:0.010434:0.005798:0.004738:0.011203:0.005371:0.004738:0.006636:0.011118:0.009476:0.011118:0.005063:0.011118:0.004738:0.006636:0.011118:0.011665:0.006636:0.003421:0.006636:0.004738:0.011682:0.010434:0.011716:0.004738:0.006636:0.011118:0.011665:0.005798:0.003421:0.011067:0.004738:0.006636:0.010434:0.011203:0.011067:0.008586:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
Crit Care Med.:@0.571006:0.843532:0.693900:0.843532:0.693900:0.829527:0.571006:0.829527:0.013906:0.005148:0.003421:0.005798:0.004738:0.013906:0.011682:0.005148:0.011118:0.004738:0.015719:0.011118:0.011716:0.004738
 2013;41:580.:@0.693883:0.843532:0.798117:0.843532:0.798117:0.829527:0.693883:0.829527:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738
5.:@0.084831:0.857643:0.099045:0.857643:0.099045:0.843638:0.084831:0.843638:0.009476:0.004738
  Klastersky J, Paesmans M, Rubenstein EB, :@0.121178:0.857643:0.461863:0.857643:0.461863:0.843638:0.121178:0.843638:0.004738:-0.004738:0.010109:0.003421:0.011682:0.006636:0.005798:0.011118:0.005148:0.006636:0.008586:0.009168:0.004943:0.008244:0.004738:0.004943:0.010126:0.011682:0.011118:0.006636:0.016044:0.011682:0.010434:0.006636:0.004943:0.015719:0.004738:0.004943:0.010382:0.010399:0.011665:0.011118:0.010434:0.006636:0.005798:0.011118:0.003421:0.010434:0.004943:0.009168:0.009818:0.004738:0.004738
et al. :@0.462068:0.857643:0.508506:0.857643:0.508506:0.843638:0.462068:0.843638:0.011118:0.005798:0.004943:0.011682:0.003421:0.004738:0.004738
The Multinational Association for Supportive Care:@0.508711:0.857643:0.915161:0.857643:0.915161:0.843638:0.508711:0.843638:0.007286:0.010434:0.011118:0.004933:0.015719:0.010399:0.003421:0.005798:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004943:0.012657:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.004943:0.005371:0.011203:0.005148:0.004935:0.008518:0.010399:0.011665:0.011665:0.011203:0.005148:0.005798:0.003421:0.009476:0.011118:0.004943:0.013906:0.011682:0.005080:0.011118
in Cancer  risk index:  a multinational scoring  system for  identifying  low-risk febrile neutropenic :@0.121178:0.871754:0.919912:0.871754:0.919912:0.857749:0.121178:0.857749:0.003421:0.010434:0.007577:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.002824:0.005148:0.003421:0.006636:0.008586:0.007577:0.003421:0.010434:0.011716:0.011118:0.008210:0.004738:0.004738:0.002829:0.011682:0.007577:0.016044:0.010399:0.003421:0.005798:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.007577:0.006636:0.011067:0.011203:0.005148:0.003421:0.010434:0.011511:0.004738:0.002826:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.007577:0.005371:0.011203:0.005148:0.004738:0.002824:0.003421:0.011716:0.011118:0.010434:0.005798:0.003421:0.005371:0.009168:0.003421:0.010434:0.011511:0.004738:0.002829:0.003421:0.011203:0.014214:0.005679:0.005148:0.003421:0.006636:0.008586:0.007577:0.005371:0.011118:0.011665:0.005148:0.003421:0.003421:0.011118:0.007577:0.010434:0.011118:0.010399:0.005798:0.005071:0.011203:0.011665:0.011118:0.010434:0.003421:0.011067:0.004738
cancer patients. :@0.121178:0.885865:0.262460:0.885865:0.262460:0.871860:0.121178:0.871860:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
J Clin Oncol.:@0.262443:0.885865:0.367070:0.885865:0.367070:0.871860:0.262443:0.871860:0.008244:0.004738:0.013906:0.003421:0.003421:0.010434:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2000;18:3038-3051.:@0.367070:0.885865:0.524362:0.885865:0.524362:0.871860:0.367070:0.871860:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
Source: UpToDate © 2018 (https://www.uptodate.com/contents/image?imageKey=ID%2F57616&topicKey=ID%2F1:@0.084848:0.921804:0.912126:0.921804:0.912126:0.909549:0.084848:0.909549:0.007453:0.009803:0.009100:0.004505:0.009683:0.009728:0.004146:0.004146:0.009803:0.010207:0.006376:0.009803:0.011135:0.010222:0.005074:0.009728:0.004146:0.011180:0.004146:0.008291:0.008291:0.008291:0.008291:0.004146:0.005523:0.009129:0.005074:0.005074:0.010207:0.005807:0.004146:0.006540:0.006540:0.012437:0.012437:0.012437:0.004146:0.009100:0.010207:0.005074:0.009803:0.010252:0.010222:0.005074:0.009728:0.004146:0.009683:0.009803:0.014038:0.006540:0.009683:0.009803:0.009129:0.005074:0.009728:0.009129:0.005074:0.005807:0.006540:0.002993:0.014038:0.010222:0.010072:0.009728:0.008845:0.002993:0.014038:0.010222:0.010072:0.009728:0.008845:0.009728:0.008022:0.009070:0.003382:0.011135:0.011599:0.008291:0.007259:0.008291:0.008291:0.008291:0.008291:0.008291:0.011329:0.005074:0.009803:0.010207:0.002993:0.009683:0.008845:0.009728:0.008022:0.009070:0.003382:0.011135:0.011599:0.008291:0.007259:0.008291
6888&source=outline_link):@0.084848:0.935036:0.271493:0.935036:0.271493:0.922781:0.084848:0.922781:0.008291:0.008291:0.008291:0.008291:0.011329:0.005807:0.009803:0.009100:0.004505:0.009683:0.009728:0.009070:0.009803:0.009100:0.005074:0.002993:0.002993:0.009129:0.009728:0.007483:0.002993:0.002993:0.009129:0.007513:0.005523